Redirigiendo al acceso original de articulo en 20 segundos...
Inicio  /  Cancers  /  Vol: 12 Par: 11 (2020)  /  Artículo
ARTÍCULO
TITULO

Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program

Ellen Warner    
Siqi Zhu    
Donald B. Plewes    
Kimberley Hill    
Elizabeth A. Ramsay    
Petrina A. Causer    
Jean Seely    
Roberta A. Jong    
Pamela Lenkov    
Christine Elser    
Pavel Crystal    
Martin J. Yaffe    
Vasily Giannakeas    
Ping Sun and Steven A. Narod    

Resumen

Women with a BRCA1 or BRCA2 gene mutation have up to an 80% lifetime risk of breast cancer unless their breasts are surgically removed, but many decline or defer surgery and choose screening, hoping that if cancer occurs, it will be detected at a curable stage. In this study 489 women with a BRCA1 or BRCA2 mutation aged from 25 to 65 years, who had never had breast or ovarian cancer, were screened annually with breast magnetic resonance imaging (MRI) in addition to mammography and were followed for an average of 13 years (range: 9 to 23 years). Ninety-five of the 489 women enrolled in the study had a bilateral preventive mastectomy in the follow-up period. Of the 91 women diagnosed with breast cancer, four died of breast cancer. The most common cause of death was ovarian cancer. For women with BRCA mutations who choose annual screening with MRI and mammography, the probability of dying of breast cancer within 20 years is 2%.

PÁGINAS
pp. 0 - 0
REVISTAS SIMILARES

 Artículos similares